Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance

Inclusion Criteria:

- Body Mass Index (BMI) of either 30 kg/m^2 or more or BMI of less than 30 kg/m^2 to 27
kg/m^2 with presence of co-morbidities

- Stable body weight during the previous 3 months (less than 5 kg self-reported weight
change)

- Previously undergone dietary weight loss and was not able to maintain reduced weight

Exclusion Criteria:

- Diagnosis of type 1 or type 2 diabetes

- Previous treatment with GLP-1 (glucagon-like peptide-1) receptor agonists (including
liraglutide or exenatide), within the last 3 months

- Visit 1 thryoid stimulating hormone (TSH) outside of the range of 0.4-6.0 mIU/L

- History of chronic pancreatitis or idiopathic acute pancreatitis

- Obesity induced by other endocrinologic disorders (e.g., Cushing Syndrome)

- Current or history of treatment with medications that may cause significant weight
gain for at least 3 months before this trial

- Current participation in an organized diet reduction program (or within the last 3
months)

- Currently using or have used within three months before this trial: pramlintide,
sibutramine, orlistat, zonisamide, topiramate, phenteremine, or metformin

- Previous surgical treatment for obesity (excluding liposuction if performed more than
one year before trial entry)

- History of major depressive disorder or a PHQ-9 (Patient Health Questionnaire-9) score
of more than 15 within the last 2 years or history of other severe psychiatric
disorders or diagnosis of an eating disorder

- Subjects with a lifetime history of a suicide attempt or history of any suicidal
behavior within the past month before entry into the trial